Search results
Results From The WOW.Com Content Network
Lacosamide, sold under the brand name Vimpat among others, is a medication used for the treatment of partial-onset seizures and primary generalized tonic-clonic seizures. [2] It is used by mouth or intravenously .
Levetiracetam, sold under the brand name Keppra among others, is a novel antiepileptic drug [7] used to treat epilepsy. [8] It is used for partial-onset , myoclonic , or tonic–clonic seizures, [ 7 ] and is taken either by mouth as an immediate or extended release formulation or by injection into a vein .
An equianalgesic chart is a conversion chart that lists equivalent doses of analgesics (drugs used to relieve pain). Equianalgesic charts are used for calculation of an equivalent dose (a dose which would offer an equal amount of analgesia) between different analgesics. [1]
There is no indication that a dog with this type of cancer could avoid surgery. If the tumor is small and can be removed completely, the dog will have a much better prognosis. If surgery is not an ...
Switching to a new type of antidepressant may help reverse any weight gain you’ve experienced during treatment. Research shows that approximately one-third of people with depression have ...
Based on the 2010 guidelines from the International League against Epilepsy (ILAE), DRE is officially diagnosed following a lack of therapeutic relief in the form of continued seizure burden after trialing at least two antiepileptic drugs (AEDs) at the appropriate dosage and duration. [1] [2] The probability that the next medication will ...
This is the list of Schedule IV controlled substances in the United States as defined by the Controlled Substances Act. [1] The following findings are required for substances to be placed in this schedule: [2] The drug or other substance has a low potential for abuse relative to the drugs or other substances in schedule III.
RR 1.31 (1.16 to 1.47) Moderate: Leaving the study early for any reason: Valproate in combination with antipsychotics may slightly reduce the chance of leaving the study early, but the difference between the two treatments is not clear. Data supporting this finding are based on moderate quality evidence. RR 0.76 (0.47 to 1.24) Moderate